Marcela Teatin Latancia
Overview
Explore the profile of Marcela Teatin Latancia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
70
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moreno N, Korchak E, Latancia M, DOrlando D, Adegbenro T, Bezsonova I, et al.
bioRxiv
. 2024 Oct;
PMID: 39416117
DNA polymerase eta (Pol η) is a Y-family translesion polymerase responsible for synthesizing new DNA across UV-damaged templates. It is recruited to replication forks following mono-ubiquitination of the PCNA DNA...
2.
Latancia M, da Silva Leandro G, Bastos A, Moreno N, Ariwoola A, Martins D, et al.
DNA Repair (Amst)
. 2024 Jul;
141:103715.
PMID: 39029375
Glioblastoma (GBM) is a highly aggressive brain tumor associated with poor patient survival. The current standard treatment involves invasive surgery, radiotherapy, and chemotherapy employing temozolomide (TMZ). Resistance to TMZ is,...
3.
Teixeira A, Ramalho M, de Souza I, Andrade I, Osawa I, Guedes C, et al.
Genet Mol Biol
. 2024 Jun;
47(Suppl 1):e20230317.
PMID: 38829285
In the search for alternatives to overcome the challenge imposed by drug resistance development in cancer treatment, the modulation of autophagy has emerged as a promising alternative that has achieved...
4.
Ribeiro D, Latancia M, de Souza I, Ariwoola A, Mendes D, Rocha C, et al.
Biosci Rep
. 2024 May;
44(5).
PMID: 38717250
Temozolomide (TMZ) is the leading therapeutic agent for combating Glioblastoma Multiforme (GBM). Nonetheless, the persistence of chemotherapy-resistant GBM cells remains an ongoing challenge, attributed to various factors, including the translesion...
5.
Ashton N, Jaiswal N, Moreno N, Semenova I, DOrlando D, Latancia M, et al.
J Mol Biol
. 2023 Nov;
435(24):168353.
PMID: 37935254
The Y-family DNA polymerases - Pol ι, Pol η, Pol κ and Rev1 - are most well-known for their roles in the DNA damage tolerance pathway of translesion synthesis (TLS)....
6.
Almeida Lima K, Osawa I, Ramalho M, de Souza I, Guedes C, Souza Filho C, et al.
Biomedicines
. 2023 May;
11(4).
PMID: 37189700
The transcription factor NRF2 is constitutively active in glioblastoma, a highly aggressive brain tumor subtype with poor prognosis. Temozolomide (TMZ) is the primary chemotherapeutic agent for this type of tumor...
7.
Rocha C, Rocha A, Silva M, Gomes L, Latancia M, Andrade Tomaz M, et al.
Cells
. 2020 Dec;
9(12).
PMID: 33271924
Glioblastoma is a severe type of brain tumor with a poor prognosis and few therapy options. Temozolomide (TMZ) is one of these options, however, with limited success, and failure is...
8.
Miyagi M, Latancia M, Testagrossa L, Andrade-Oliveira V, Pereira W, Hiyane M, et al.
Mol Immunol
. 2018 Aug;
101:507-513.
PMID: 30144701
Cisplatin is a chemotherapy used to treat different types of cancer, such as testicular, bladder and head and neck. Physical exercise has been shown to improve cancer therapy and recently,...
9.
Castoldi A, Andrade-Oliveira V, Aguiar C, Amano M, Lee J, Miyagi M, et al.
Cell Rep
. 2017 Jun;
19(11):2272-2288.
PMID: 28614714
The underlying mechanism by which MyD88 regulates the development of obesity, metainflammation, and insulin resistance (IR) remains unknown. Global deletion of MyD88 in high-fat diet (HFD)-fed mice resulted in increased...